KLOW80
An advanced regenerative and anti-inflammatory research blend combining GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg and KPV 10 mg to investigate extracellular-matrix remodelling, tissue protection, cellular migration and inflammatory-pathway regulation within one fixed formulation.
GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg. The selector describes the vial format and must not be interpreted as a dose.
Interested in this compound?
Contact the PHONYX team for availability and catalogue information.
What is KLOW80?
KLOW80 is a fixed 80 mg multi-component peptide blend developed for research into regeneration, inflammatory control, structural tissue support and adaptation to physical stress. It expands the GLOW70 concept by adding KPV, a short peptide associated with anti-inflammatory and mucosal-barrier signalling.
The formulation combines four complementary research domains: GHK-Cu for collagen, elastin and extracellular-matrix biology; BPC-157 for cytoprotection, angiogenesis and fibroblast-related pathways; TB-500 for actin-associated cell migration and tissue remodelling; and KPV for inflammatory-pathway and barrier-tissue research.
Four complementary biological pathways
GHK-Cu — matrix support
GHK-Cu is investigated for copper transport, collagen and elastin production, glycosaminoglycan synthesis, extracellular-matrix remodelling and regulation of oxidative and inflammatory signalling.
BPC-157 — tissue protection
BPC-157 is associated with VEGF/VEGFR2 and nitric-oxide signalling, fibroblast migration, angiogenesis, gastrointestinal cytoprotection and connective-tissue repair models.
TB-500 — cellular migration
TB-500-related research focuses on actin dynamics, cell migration, cytoskeletal organization, tissue mobility and recovery-associated remodelling.
KPV — inflammatory regulation
KPV is investigated in relation to NF-κB-associated signalling, inflammatory cytokines, immune regulation and mucosal-barrier homeostasis.
GLOW70 compared with KLOW80
| Blend | Components | Total | Primary research emphasis |
|---|---|---|---|
| GLOW70 | GHK-Cu + BPC-157 + TB-500 | 70 mg | Regeneration, matrix remodelling and repair signalling |
| KLOW80 | GHK-Cu + BPC-157 + TB-500 + KPV | 80 mg | Regeneration plus inflammatory and barrier-tissue regulation |
Research applications of the component pathways
Connective tissue Tendons, ligaments, fascia and matrix
The blend combines collagen and extracellular-matrix signalling with pathways associated with fibroblast activity, cell migration and tissue remodelling.
Inflammatory regulation Cytokine and NF-κB-related research
KPV and BPC-157 contribute complementary research interest in inflammatory signalling and the biological environment surrounding tissue repair.
Skin and structural support Collagen, elastin and cellular renewal
GHK-Cu contributes matrix and skin-biology research, while the remaining components add protection, migration and inflammatory-regulation pathways.
Barrier tissues Mucosal and epithelial research
KPV and BPC-157 are studied in relation to mucosal homeostasis, gastrointestinal-barrier biology and inflammatory balance.
Recovery models Adaptation following physical stress
Research-oriented descriptions focus on muscle, tendon, joint and soft-tissue recovery after experimental load or injury.
Evidence limitation Fixed-blend data
Most published evidence evaluates the individual components or their pathways. Controlled human evidence for the exact fixed KLOW80 blend is not established.
KLOW80 protocol formats reported for the fixed blend
Standard regenerative
4 mg total blend, once daily, for approximately 4–8 weeks, followed by a protocol break of approximately 4–8 weeks.
Intensive recovery
8 mg total blend, once daily, for approximately 4–6 weeks, followed by a protocol break of approximately 4–8 weeks.
Fixed-ratio interpretation
Every measured amount preserves the formulation ratio of 50 parts GHK-Cu to 10 parts each of BPC-157, TB-500 and KPV.
| Research protocol | Total blend amount | Approximate component amounts | Frequency | Active period | Break |
|---|---|---|---|---|---|
| Standard regenerative | 4 mg | 2.5 mg GHK-Cu + 0.5 mg BPC-157 + 0.5 mg TB-500 + 0.5 mg KPV | Once daily | 4–8 weeks | Approximately 4–8 weeks |
| Intensive recovery | 8 mg | 5 mg GHK-Cu + 1 mg BPC-157 + 1 mg TB-500 + 1 mg KPV | Once daily | 4–6 weeks | Approximately 4–8 weeks |
Outcomes associated with the combined pathways
Collagen and elastin
GHK-Cu-related research describes extracellular-matrix synthesis, organization and structural support.
Angiogenic signalling
BPC-157-related models examine VEGF, nitric oxide and local vascular support.
Repair-associated cells
TB-500-related pathways are linked to actin regulation and cellular movement.
Barrier and cytokine balance
KPV-related research focuses on inflammatory signalling and mucosal-barrier regulation.
The rationale for KLOW80 is mechanistic complementarity. Evidence for the individual components does not automatically establish the safety or efficacy of the fixed combination.
Reported observations and unresolved risks
Research-oriented descriptions commonly mention mild, temporary observations such as local redness, transient discomfort, headache, fatigue or mild puffiness. Less common observations include gastrointestinal discomfort, dizziness or individual sensitivity to one of the components.
Controlled human safety data for the exact fixed blend remain limited. Important unresolved issues include systemic copper exposure, angiogenesis-related risks, immunogenicity, inflammatory-pathway interactions, long-term effects and the combined pharmacology of all four components.
A fixed blend with four distinct biological profiles
GHK-Cu, BPC-157, TB-500 and KPV differ in sequence, molecular properties, tissue distribution and biological persistence. The fixed mass ratio ensures consistent composition but does not imply equal half-lives or identical target engagement.
PHONYX portfolio format
Evidence behind the component mechanisms
Frequently asked questions
What does KLOW80 contain?
GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg and KPV 10 mg, for 80 mg total material.
How does KLOW80 differ from GLOW70?
KLOW80 adds 10 mg KPV, introducing an additional anti-inflammatory and barrier-tissue research pathway.
Why is KPV included?
KPV is studied for inflammatory regulation, cytokine signalling and mucosal-barrier homeostasis.
What protocol is described for standard regenerative research?
The requested PeptidePower source describes 4 mg total blend once daily for four to eight weeks, followed by approximately four to eight weeks off.
What protocol is described for intensive recovery research?
The requested source describes 8 mg total blend once daily for four to six weeks, followed by approximately four to eight weeks off.
How much of each component is present in 4 mg?
Approximately 2.5 mg GHK-Cu and 0.5 mg each of BPC-157, TB-500 and KPV.
How much of each component is present in 8 mg?
Approximately 5 mg GHK-Cu and 1 mg each of BPC-157, TB-500 and KPV.
Is 80 mg a single administration?
No. It is the total lyophilized content of the vial.
Is KLOW80 clinically approved?
No. The fixed blend is not an approved medicinal product.
Does evidence for each peptide prove the blend works?
No. Component evidence does not automatically establish the safety or efficacy of the fixed combination.
Research Disclaimer
This compound is presented exclusively for laboratory and scientific research. It is not intended for human consumption, self-administration, diagnostic use, treatment, cure or prevention of disease. Information describing research protocols is provided solely for documentary and educational context and must not be interpreted as medical advice, a dosing recommendation or instructions for use. KLOW80 is not an approved medicinal product, and its clinical safety and efficacy remain unestablished.